StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) bonds

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)

Close on Nov 17, 2026Market cap $73.93MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Coherus Oncology reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Coherus Oncology's 10-K for the period ended Dec 31, 2025

IssueCouponAmount issuedCarrying value
2027 Term LoansFloating + 1.00%$250.00M–
2029 Term Loans––$54.42M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.

See a number that looks wrong?